Whelan Financial’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$513K Buy
1,962
+265
+16% +$67.9K 0.13% 57
2026
Q2
$427K Sell
1,697
-91
-5% -$19.6K 0.12% 64
2026
Q1
$389K Buy
1,788
+73
+4% +$16.2K 0.12% 61
2025
Q4
$392K Sell
1,715
-434
-20% -$98.9K 0.12% 58
2025
Q3
$498K Buy
2,149
+988
+85% +$201K 0.16% 51
2025
Q2
$215K Sell
1,161
-43
-4% -$7.99K 0.08% 60
2025
Q1
$252K Buy
1,204
+16
+1% +$3.11K 0.1% 54
2024
Q4
$211K Buy
+1,188
New +$218K 0.08% 57

Other funds holding ABBV

Whelan Financial's ABBV Position: Q3 2026 in Review

Whelan Financial increased its AbbVie (ABBV) stake by 16% in Q3 2026, buying an estimated $67.9K and bringing the position to 1,962 shares worth $513K. The position accounts for 0.13% of the portfolio, ranked #57.

Whelan Financial first reported a position in ABBV in Q4 2024 and has held it in 8 quarters since. 4,250 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Whelan Financial held 1,962 shares of AbbVie worth $513K as of Q3 2026.
  • Whelan Financial bought 265 AbbVie shares in Q3 2026, an estimated $67.9K.
  • AbbVie made up 0.13% of Whelan Financial's portfolio in Q3 2026, its #57 holding.
  • Whelan Financial first reported a position in AbbVie in Q4 2024 and has held it in 8 quarters since.
  • 4,250 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Whelan Financial's 13F filing for Q3 2026, filed 28 Oct 2026.